Breast Cancer Subtypes and Metastasis Timing: An Analysis of German Cancer Registry Data (2000–2024)

Molecular subtypes of breast cancer are associated with both the timing and the organ-specific distribution of metastatic disease, according to a large registry-based analysis covering nearly a quarter century of diagnoses in Germany. The study, published in the Journal of Cancer Research and Clinical Oncology, drew on data from nine regional cancer registries and included 172,512 women diagnosed with invasive breast cancer between January 2000 and March 2024. Patients were classified as having no metastases, synchronous metastases within three months of diagnosis, or metachronous metastases.

Factors associated with synchronous metastases were assessed using multivariable binary logistic regression adjusted for confounders. Time to first metachronous metastasis was analyzed using multivariable Cox regression.

Compared with hormone receptor-positive and HER2-negative tumors, tumors that were hormone receptor-negative but HER2-positive showed the highest odds of synchronous metastasis, with an adjusted odds ratio of 1.69 and a 95 percent confidence interval of 1.57 to 1.83. In sharp contrast, triple-negative tumors, those lacking both hormone receptors and HER2, showed no increased odds of synchronous spread at all, with an adjusted odds ratio of 0.96 and a confidence interval spanning 0.90 to 1.02.

Triple-negative tumors carried the highest risk of developing metastases later in the disease course, with an adjusted hazard ratio of 1.48 and a 95 percent confidence interval of 1.41 to 1.55. Meanwhile, tumors positive for both hormone receptors and HER2 showed a lower risk of metachronous metastasis than hormone receptor-positive, HER2-negative tumors, with an adjusted hazard ratio of 0.88 and a confidence interval of 0.84 to 0.93.

Cumulative incidence of metastatic disease increased between five and ten years after diagnosis, with a notably late risk among hormone receptor-positive tumors.

Organ-specific patterns also differed markedly across molecular subtypes. Hormone receptor-positive, HER2-negative tumors showed predominantly bone metastases.

The authors conclude that molecular subtypes influence both the timing and the distribution of metastatic breast cancer. HER2-positive tumors are associated with synchronous metastatic presentation, whereas HR−/HER2− tumors showed the highest risk of metachronous metastasis.

These findings support subtype-specific risk assessment and surveillance strategies.

Nevertheless, the analysis is observational and registry-based, so it identifies associations rather than experimentally demonstrated mechanisms.

Subject of Research: Association of breast cancer molecular subtypes with the timing and organ-specific patterns of metastatic disease in German cancer registry data

Article Title: Determinants of synchronous and metachronous metastatic breast cancer (2000–2024)–an analysis based on data from German cancer registries

Article References: Lacruz, M. E., Bedir, A., Wittenberg, I., Thies, S., Schneider, C., Reinwald, F., Hoffmann, W., Faißt, S., Franke, B., Kleihues, K., Zeissig, S. R., Klinkhammer-Schalke, M., Gerken, M., Sturm-Inwald, E. C., & Ignatov, A. (2026). Determinants of synchronous and metachronous metastatic breast cancer (2000–2024)–an analysis based on data from German cancer registries. Journal of Cancer Research and Clinical Oncology, 152(11), Article 216. https://doi.org/10.1007/s00432-026-06631-5

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06631-5

Keywords: breast cancer, metastasis, molecular subtypes, HER2, triple-negative, hormone receptor, cancer registries, synchronous metastases, metachronous metastases, surveillance, bone metastases, visceral metastases